改良FOLFOX6化疗用于转移性脐尿管癌患者
Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer.
作者信息
Yanagihara Yutaka, Tanji Nozomu, Miura Noriyoshi, Shirato Akitomi, Nishimura Kenichi, Fukumoto Tetsuya, Azuma Koji, Miyauchi Yuki, Kikugawa Tadahiko, Yokoyama Masayoshi
机构信息
Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan.
出版信息
Chemotherapy. 2013;59(6):402-6. doi: 10.1159/000362400. Epub 2014 Jun 25.
BACKGROUND
To improve the prognosis of patients with urachal cancer and establish an effective chemotherapeutic regimen for distant metastases.
METHODS
We conducted a retrospective study to evaluate the efficacy and safety of a modified combination of 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) therapy in patients with metastatic urachal cancer.
RESULTS
Five patients were treated with mFOLFOX6. Their median age was 65 years (range 41-80). The median follow-up time was 42 months (range 18-46). Two of the 5 patients (40%) showed an objective response: 1 achieved a clinically complete response and 1 a partial response. The grade 3/4 toxicity associated with this regimen was primarily neutropenia, but febrile neutropenia was not observed. Oxaliplatin treatment was discontinued because of a grade 2 allergic reaction in 1 patient. Grade 2 peripheral sensory neuropathy caused by oxaliplatin was observed in 2 patients, and the OPTIMOX (stop and go) approach had to be adopted.
CONCLUSIONS
mFOLFOX6 appears to be effective for the treatment of metastatic urachal cancer.
背景
为改善脐尿管癌患者的预后并建立针对远处转移的有效化疗方案。
方法
我们进行了一项回顾性研究，以评估改良的5-氟尿嘧啶、亚叶酸钙和奥沙利铂联合方案（mFOLFOX6）治疗转移性脐尿管癌患者的疗效和安全性。
结果
5例患者接受了mFOLFOX6治疗。他们的中位年龄为65岁（范围41-80岁）。中位随访时间为42个月（范围18-46个月）。5例患者中有2例（40%）出现客观缓解：1例达到临床完全缓解，1例部分缓解。与该方案相关的3/4级毒性主要是中性粒细胞减少，但未观察到发热性中性粒细胞减少。1例患者因2级过敏反应停用奥沙利铂治疗。2例患者出现由奥沙利铂引起的2级周围感觉神经病变，不得不采用OPTIMOX（停停走走）方案。
结论
mFOLFOX6似乎对转移性脐尿管癌的治疗有效。
Zotero 插件